Unnecessary IV Antibiotic Days Using General Criteria for Antibiotic Switch
1 other identifier
observational
187
1 country
2
Brief Summary
Observation of the use of intravenous antibiotics in medical clinic of Sorlandet Hospital, Norway. Suggestions of criteria for the switch from intravenous to oral administration of antibiotics. Implementation of the criteria and new registration of the use of intravenous antibiotics. Comparison of the amount of the iv-administration before and after the intervention.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Nov 2006
Shorter than P25 for all trials
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 1, 2006
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2007
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2007
CompletedFirst Submitted
Initial submission to the registry
August 16, 2007
CompletedFirst Posted
Study publicly available on registry
September 30, 2008
CompletedSeptember 30, 2008
September 1, 2008
2 months
August 16, 2007
September 29, 2008
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Reduction in the amount of intravenous antibiotic days
During stay
Secondary Outcomes (1)
Hospital stay duration, re-admittance, re-prescription of intravenous antibiotic therapy
4 weeks
Study Arms (2)
1
Observation group
2
Intervention group
Interventions
Implementation of antibiotic switch guidelines
Eligibility Criteria
You may qualify if:
- Alle patients with suspected infection and who is gives intravenous antibiotics
You may not qualify if:
- CNS-infection
- Endocarditis
- Bone/joint infection
- Undrained abscess
- Foreign body infection
- Compromized oral route
- Immunosuppression
- Patients meeting the systemic inflammatory response syndrome criteria
- No preferred oral antibiotic available
- Other conditions requiring intravenous administration
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
Sorlandet Sykehus Arendal
Arendal, Aust-Agder, 4500, Norway
Sørlandet Sykehus Kristiansand
Kristiansand, Vest Agder, 4604, Norway
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Bjoern Waagsboe, Ass dr
Medical department Kristiansand
- STUDY DIRECTOR
Anders Sundoy, Chief Doc
Medical dep kristiansand
- STUDY DIRECTOR
Else Quist Paulsen, ass doc
Med dep Arendal
Study Design
- Study Type
- observational
- Sponsor Type
- OTHER GOV
Study Record Dates
First Submitted
August 16, 2007
First Posted
September 30, 2008
Study Start
November 1, 2006
Primary Completion
January 1, 2007
Study Completion
March 1, 2007
Last Updated
September 30, 2008
Record last verified: 2008-09